If you need help accessing our website, call 855-698-9991
Skip to main content
Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.

Stephen Ross, MD

Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.
  • Specialties: Psychiatry, Addiction Psychiatry
  • Treats: Adults
  • Language: English
  • Phone: 212-263-6289
View Locations

Board Certifications
  • American Board of Psychiatry & Neurology (Addiction Psychiatry), 2004
  • American Board of Psychiatry & Neurology - Psychiatry, 2002
Education and Training
  • Fellowship, NYU Grossman School of Medicine, Addiction Psychiatry, 2002
  • MD from University Of Ca Los Angeles, 1996

Is this your profile?

Edit profile

Please call the office for information about accepted insurance plans.

Stephen Ross, MD does not accept insurance.

Locations and Appointments

462 First Avenue, New York, NY 10016

Research Summary

Dr. Stephen Ross is a Research Associate Professor in the Departments of Psychiatry and Child and Adolescent Psychiatry at NYU Grossman School of Medicine. Dr. Ross is a founding member of the NYU Psychedelic Research Group and is currently associate director of NYU Langone’s Center for Psychedelic Medicine and director of the Psychedelic Medicine Research Training Program. In 21 years at NYU Langone and NYC Health + Hospitals/Bellevue, Dr. Ross has been involved in a variety of leadership roles in administration, teaching, and research. He previously served as Director of the Division of Alcoholism and Drug Abuse in the Psychiatry Department at Bellevue for 12 years, Director of Addiction Psychiatry at NYU Langone’s Tisch Hospital, Director of the NYU Addiction Psychiatry Fellowship, Director of the Bellevue Inpatient Dual Diagnosis Training Unit, and Director of the Bellevue Opioid Overdose Prevention Program. Dr. Ross has received over a dozen teaching awards at NYU Langone and nationally over the last 21 years. Dr. Ross’s main research interests focus on developing novel pharmacologic-psychosocial approaches to treating addictive disorders, including the intersection between pain and addiction; psychiatric and existential distress associated with advanced or terminal cancer; major depression; PTSD; and personality disorders. Dr. Ross is principal investigator or co-principal investigator on several ongoing and completed psychedelic-focused studies at NYU Langone including a phase II RCT studying the efficacy of psilocybin-assisted psychotherapy in patients with life-threatening cancer-related psychiatric and existential distress, a phase II RCT studying the effects of psilocybin-assisted psychotherapy in alcohol use disorder, a phase I/II controlled trial administering psilocybin to religious professionals, and a phase II RCT of psilocybin treatment for major depressive disorder. Dr. Ross also acts as a co-investigator and study therapist for phase II/III trials of MDMA-assisted psychotherapy for PTSD and is an expert in cannabinoid therapeutics and PI of a NIDA-funded study of CBD administration in patients with chronic radicular pain on chronic opioid therapy.

Academic Contact

Academic office

462 First Avenue

New York, NY 10016



  • Treatments for opioid addiction exist but effectiveness is compromised when subjects use illicit opiates during treatment. Reuse rates during treatment can be high and reducing illicit opiate use during treatment has thus recently become a major NIDA po

    Learn More
  • This trial is designed to evaluate efficacy and psychological mechanisms of single-dose psilocybin-assisted psychotherapy (PAP) to treat psychiatric (anxiety depression) and existential distress (demoralization death anxiety) and quality-of-life (QOL)

    Learn More
View All Research Studies (2)

Read All Publications (64)

Related News